Dr Vaibhav Choudhary

Dr. Vaibhav Choudhary is widely regarded for integrating precision oncology and immunotherapy into routine cancer care, offering advanced, personalised treatment plans for complex and late-stage cancers. He is actively involved in global clinical research, contributes to high-impact oncology publications, and collaborates with international cancer societies. His expertise in genomic testing, liquid biopsy and targeted therapies enables cutting-edge treatment options for patients requiring specialised and advanced oncology care.

Educational Qualifications:

• MBBS – Government Medical College, Nagpur (2007)
• MD (General Medicine) – AIIMS, New Delhi (2011)
• DM (Medical Oncology) – Tata Memorial Hospital, Mumbai (2015)
• ESMO Certification in Medical Oncology (2015)
• MRCP – Specialty Certificate in Medical Oncology (SCE), Royal College of Physicians, UK (2016)
• Certification – Genetics & Precision Oncology, Cancer Immunotherapy & Gene Therapy, Harvard Medical School (2023)

Professional Experience:

• Director - Medical & Precision Oncology, Nanavati Max Super Speciality Hospital, Mumbai (2025–Present)
• Consultant – Medical Oncology, Kokilaben Hospital, Mumbai (2023–2025)
• Consultant – Medical Oncology, American Oncology Institute, Nagpur (2022–2023)
• Consultant – Medical Oncology, Wockhardt Hospitals, Nagpur (2019–2022)
• Consultant & Head – Medical Oncology, HCG Cancer Centre, Nagpur (2018–2019)
• Specialist Senior Resident – Medical Oncology, Tata Memorial Hospital, Mumbai (2015–2016)
• Senior Resident – Medical Oncology, Tata Memorial Hospital, Mumbai (2012–2015)
• Senior Resident – Medical Oncology, AIIMS IRCH, New Delhi (2011–2012)

Professional Memberships:

• American Society of Clinical Oncology (ASCO)
• European Society of Medical Oncology (ESMO)
• Indian Society of Medical and Pediatric Oncology (ISMPO)
• International Society of Liquid Biopsy (ISLB)
• Society for Immunotherapy of Cancer (SITC)

Research Papers & Publications:

• “Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial” – published in JCO Global Oncology (2024).
• “PDL1 Expression Testing in Head and Neck Squamous Cell Carcinoma: Bridging the Gap” – Indian Journal of Cancer (2023).
• “Evolution of Biomarkers and Treatment Outcomes of Immunotherapy in Lung Cancer in Current Tissue Microenvironment” – by Kaler A.K., Maskomani S., Ritambhara, Kavyashree, Varsha Vadera, Vaibhav Choudhary, Imran Shaikh, Sandeep Goyle & Rajesh Mistry (2023).
• “Comprehensive Genomic Profiling in Breast Cancer – Is it Ready for Prime Time Use?” – Choudhary V., Gupta S., published in Current Breast Cancer Reports (2016).
• “Targeted Therapy of Soft Tissue Sarcoma: There is More than One Way to Skin a Cat!” – Bajpai J., Choudhary V., in Chemo Open Access (2016).
• “Status of Cancer Research in India” IACR (2015).